Screen LibraryCancer immunotherapy : paradigms, practice and promise /
This volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical tr...
Saved in:
| Corporate Authors: | |
|---|---|
| Group Author: | |
| Published: |
Springer,
|
| Publisher Address: | New York, NY : |
| Publication Dates: | 2013. |
| Literature type: | eBook |
| Language: | English |
| Subjects: | |
| Online Access: |
http://dx.doi.org/10.1007/978-1-4614-4732-0 |
| Summary: |
This volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical trials are also discussed, as are key pre-clinical developments. The major challenges and intellectual issues facing investigators developing novel immunotherapeutics are discussed in detail as are conceptual developments influencing current and future treatment strategies.Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy.Although the field is evolving rapidly, we have taken pains to ensure that information was as up to date as possible as the text went to press. |
| Carrier Form: | 1 online resource |
| Bibliography: | Includes bibliographical references and index. |
| ISBN: |
9781461447320 (electronic bk.) 1461447321 (electronic bk.) |
| Index Number: | RC271 |
| CLC: | R730.51 |
| Contents: |
Overview -- Historical Perspectives and Current Trends in Cancer Immunotherapy / T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment / Passive strategies to boost anti-tumor immunity -- Adoptive T Cell Transfer / Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts / Active strategies to boost anti-tumor immunity -- Peptide and Protein-Based Cancer Vaccines / Antigen Targeting to Dendritic Cells for Cancer Immunotherapy / Cytokines in the Treatment of Cancer / Immune Co-signaling to Treat Cancer / Managing Regulatory T Cells to Improve Cancer Immunotherapy / Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives / Antibodies as Cancer Immunotherapy / Targeted Toxins in Cancer Immunotherapy / Additional strategies and considerations -- Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokine Agents, Infectious Agents, Tumor Stroma Targeting, Age and Sex Effects, and Miscellaneous Small Molecules / Monitoring Antigen-Specific Responses in Clinical Trials of Cancer Immunotherapy / Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies / |